{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:21:40Z","timestamp":1791584500260,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":102,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005339","name":"American Academy of Neurology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015646","name":"OMRON Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017024","name":"Salah Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000971","name":"Amyotrophic Lateral Sclerosis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000971","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NeuroImage: Clinical"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.nicl.2021.102672","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T09:07:40Z","timestamp":1618564060000},"page":"102672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial"],"prefix":"10.1016","volume":"30","author":[{"given":"Suma","family":"Babu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baileigh G.","family":"Hightower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"Z\u00fcrcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Kivis\u00e4kk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-En J.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica L.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Robichaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Banno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armineuza","family":"Evora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshata","family":"Ashokkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Pothier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Paganoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Dojillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gudesblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merit E.","family":"Cudkowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M","family":"Hooker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazem","family":"Atassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nicl.2021.102672_b0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2967\/jnumed.116.178335","article-title":"Pseudoreference regions for glial imaging with (11)C-PBR28: investigation in 2 clinical cohorts","volume":"59","author":"Albrecht","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"24","key":"10.1016\/j.nicl.2021.102672_b0010","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1212\/WNL.0000000000003427","article-title":"Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis","volume":"87","author":"Alshikho","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nicl.2021.102672_b0015","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/ana.25251","article-title":"Integrated magnetic resonance imaging and [(11) C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis","volume":"83","author":"Alshikho","year":"2018","journal-title":"Ann. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.nicl.2021.102672_b0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/21678421.2019.1672750","article-title":"Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis","volume":"21","author":"Babu","year":"2020","journal-title":"Amyotroph Lateral Scler. Frontotemporal Degener."},{"issue":"1607","key":"10.1016\/j.nicl.2021.102672_b0025","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2014.10.031","article-title":"Use of biomarkers in ALS drug development and clinical trials","volume":"14","author":"Bakkar","year":"2015","journal-title":"Brain Res."},{"issue":"13","key":"10.1016\/j.nicl.2021.102672_b0030","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","article-title":"Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?","volume":"74","author":"Barkhof","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.nicl.2021.102672_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039216","article-title":"Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis","volume":"7","author":"Brettschneider","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nicl.2021.102672_b0040","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, and the NFL Group, et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol 2019 Jun 17."},{"issue":"5","key":"10.1016\/j.nicl.2021.102672_b0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"World federation of neurology research group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotroph. Lateral Scler. Other Motor Neuron Disord."},{"issue":"sup1","key":"10.1016\/j.nicl.2021.102672_b0050","first-page":"1","article-title":"Novel composite endpoint extended analysis during extension of Ibudilast Phase 1a\/2b clinical trial better predicts post-wash-out survival","volume":"19","author":"Brooks","year":"2018","journal-title":"Platform Commun. Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"10.1016\/j.nicl.2021.102672_b0055","doi-asserted-by":"crossref","unstructured":"Canto E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, et al. Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurol 2019 Aug 12.","DOI":"10.1001\/jamaneurol.2019.2137"},{"issue":"1\u20132","key":"10.1016\/j.nicl.2021.102672_b0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.nicl.2021.102672_b0065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbrc.2020.03.051","article-title":"Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: The new molecular mechanism of ibudilast and its implication for neuroprotective therapy","volume":"526","author":"Chen","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"25","key":"10.1016\/j.nicl.2021.102672_b0070","doi-asserted-by":"crossref","first-page":"11313","DOI":"10.1073\/pnas.1002716107","article-title":"Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast","volume":"107","author":"Cho","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.nicl.2021.102672_b0075","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","author":"Coalition","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.nicl.2021.102672_b0080","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.4049\/jimmunol.1200485","article-title":"Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation","volume":"191","author":"Cox","year":"2013","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.nicl.2021.102672_b0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/JCP.0000000000000511","article-title":"Safety of intravenous methamphetamine administration during ibudilast treatment","volume":"36","author":"DeYoung","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.nicl.2021.102672_b0090","doi-asserted-by":"crossref","unstructured":"Downer OM, Marcus REG, Zurcher NR, Hooker JM. Tracing the History of the Human Translocator Protein to Recent Neurodegenerative and Psychiatric Imaging. ACS Chem Neurosci 2020 Jul 23.","DOI":"10.1021\/acschemneuro.0c00362"},{"issue":"9","key":"10.1016\/j.nicl.2021.102672_b0095","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis","volume":"379","author":"Fox","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.nicl.2021.102672_b0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0165-5728(98)00251-3","article-title":"Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats","volume":"95","author":"Fujimoto","year":"1999","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.nicl.2021.102672_b0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuroimage.2007.11.011","article-title":"Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation","volume":"40","author":"Fujita","year":"2008","journal-title":"Neuroimage"},{"issue":"1\u20133","key":"10.1016\/j.nicl.2021.102672_b0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2006.02.053","article-title":"The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family","volume":"538","author":"Gibson","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nicl.2021.102672_b0115","doi-asserted-by":"crossref","unstructured":"Ha W, Sevim-Nalkiran H, Zaman AM, Matsuda K, Khasraw M, Nowak AK, et al. Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). Sci Rep 2019 Feb 27;9(1):2905-019-39427-4.","DOI":"10.1038\/s41598-019-39427-4"},{"key":"10.1016\/j.nicl.2021.102672_b0120","doi-asserted-by":"crossref","unstructured":"Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2020 Jun 9.","DOI":"10.1002\/acn3.51078"},{"issue":"Pt 9","key":"10.1016\/j.nicl.2021.102672_b0125","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/brain\/awv184","article-title":"Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease","volume":"138","author":"Jucaite","year":"2015","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.nicl.2021.102672_b0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.21743","article-title":"Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III","volume":"66","author":"Kaufmann","year":"2009","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.nicl.2021.102672_b0135","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.dadm.2018.06.001","article-title":"Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles","volume":"2","author":"Keshavan","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"issue":"6","key":"10.1016\/j.nicl.2021.102672_b0140","first-page":"725","article-title":"Changes in the normal maximal expiratory flow-volume curve with growth and aging","volume":"127","author":"Knudson","year":"1983","journal-title":"Am. Rev. Respir. Dis."},{"issue":"10","key":"10.1016\/j.nicl.2021.102672_b0145","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"issue":"6","key":"10.1016\/j.nicl.2021.102672_b0150","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/jnnp-2015-310998","article-title":"Rate of disease progression: a prognostic biomarker in ALS","volume":"87","author":"Labra","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"22","key":"10.1016\/j.nicl.2021.102672_b0155","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nicl.2021.102672_b0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1\u20132 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.nicl.2021.102672_b0165","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/jcbfm.2012.46","article-title":"Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA","volume":"32","author":"Mizrahi","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"3","key":"10.1016\/j.nicl.2021.102672_b0170","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.neuropharm.2003.09.009","article-title":"Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia","volume":"46","author":"Mizuno","year":"2004","journal-title":"Neuropharmacology"},{"issue":"22","key":"10.1016\/j.nicl.2021.102672_b0175","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.nicl.2021.102672_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jcbfm.2011.147","article-title":"An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28","volume":"32","author":"Owen","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"3","key":"10.1016\/j.nicl.2021.102672_b0185","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mus.26385","article-title":"A pilot trial of RNS60 in amyotrophic lateral sclerosis","volume":"59","author":"Paganoni","year":"2019","journal-title":"Muscle Nerve"},{"issue":"125","key":"10.1016\/j.nicl.2021.102672_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.04.025","article-title":"An overview of platform trials with a checklist for clinical readers","volume":"13","author":"Park","year":"2020","journal-title":"J. Clin. Epidemiol."},{"issue":"12","key":"10.1016\/j.nicl.2021.102672_b0195","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1021\/acschemneuro.0c00238","article-title":"Time Will Tell the Utility of Biomarkers","volume":"11","author":"Parmar","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.nicl.2021.102672_b0200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/17482960903307805","article-title":"A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis","volume":"11","author":"Pascuzzi","year":"2010","journal-title":"Amyotroph Lateral Scler."},{"issue":"9","key":"10.1016\/j.nicl.2021.102672_b0205","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3389\/fneur.2018.01167","article-title":"Diagnostic and prognostic performance of neurofilaments in ALS","volume":"18","author":"Poesen","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.nicl.2021.102672_b0210","doi-asserted-by":"crossref","unstructured":"Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener 2016 Jul-Aug;17(5-6):414-425.","DOI":"10.3109\/21678421.2016.1140786"},{"issue":"9","key":"10.1016\/j.nicl.2021.102672_b0215","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/npp.2017.10","article-title":"Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: a randomized, placebo-controlled, human laboratory trial","volume":"42","author":"Ray","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.nicl.2021.102672_b0220","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3109\/00498250903254340","article-title":"Cross-species comparisons of the pharmacokinetics of ibudilast","volume":"39","author":"Sanftner","year":"2009","journal-title":"Xenobiotica"},{"issue":"12","key":"10.1016\/j.nicl.2021.102672_b0225","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.nicl.2021.102672_b0230","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.0000000000002941","article-title":"Quantitative strength testing in ALS clinical trials","volume":"87","author":"Shefner","year":"2016","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.nicl.2021.102672_b0235","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0006-8993(99)01666-2","article-title":"Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS","volume":"837","author":"Suzumura","year":"1999","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.nicl.2021.102672_b0240","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13311-015-0336-z","article-title":"Being PRO-ACTive: what can a clinical trial database reveal about ALS?","volume":"12","author":"Zach","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.nicl.2021.102672_b0245","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.nicl.2015.01.009","article-title":"Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28","volume":"19","author":"Zurcher","year":"2015","journal-title":"Neuroimage Clin."}],"container-title":["NeuroImage: Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213158221001169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213158221001169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:29:17Z","timestamp":1761971357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213158221001169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":49,"alternative-id":["S2213158221001169"],"URL":"https:\/\/doi.org\/10.1016\/j.nicl.2021.102672","relation":{},"ISSN":["2213-1582"],"issn-type":[{"value":"2213-1582","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial","name":"articletitle","label":"Article Title"},{"value":"NeuroImage: Clinical","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nicl.2021.102672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102672"}}